DAWN (DAWN)
Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Market Cap
—
P/E (TTM)
—
EPS
—
Div Yield
—
52W Range
—
Beta
—
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
No company overview is available for DAWN yet.
Peers in Biotechnology
All in industry →VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%
Recent press releases
DAWN has not issued a press release in this window.
SEC filings
All filings →DAWN has not filed an SEC document in this window.
Insider trades
All insider trades →DAWN has no reported insider trades in the last 90 days.
Institutional holders
All holders →As of 2025-12-31 · prior 2025-09-30
Vestal Point Capital, LP$48.5M
5,200,000 sh+94.4%
FRANKLIN RESOURCES INC$491,406
52,726 sh-98.5%
BlackRock, Inc.$82.4M
8,837,574 sh-1.8%
FMR LLC$53.3M
5,717,008 sh-43.4%
STATE STREET CORP$40.0M
4,289,566 sh+32.4%
VANGUARD GROUP INC$58.6M
6,282,376 sh+1.6%
6,412,560 sh-0.3%
CITADEL ADVISORS LLC$15.9M
1,704,513 sh+157.0%
People at DAWN
All people →Quarterly financials
Full financials →Revenue trend
03/25
$30.8M
NI -$36.0M
06/25
$33.6M
NI -$30.3M
09/25
$39.8M
NI -$19.7M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.19
Prior: $-0.29
Revenue sparkline